O-GlcNAcylation of UGDH regulates its activity and remodels the extracellular matrix to facilitate tumor growth

TL;DR

This study shows that O-GlcNAcylation of UGDH promotes tumor growth by altering the extracellular matrix and reducing immune cell infiltration.

Contribution

The study identifies UGDH O-GlcNAcylation as a novel regulator of tumor immunity and a potential target for immunotherapy.

Findings

O-GlcNAcylation of UGDH enhances its enzymatic activity and hyaluronic acid synthesis.

UGDH O-GlcNAcylation reduces CD8+ T cell infiltration by suppressing CXCL10 expression.

O-GlcNAcylation-deficient UGDH leads to reduced tumor growth and improved survival in mice.

Abstract

The tumor microenvironment is an immunosuppressive niche that contributes to tumor growth by downregulating immune cell functions or restraining immune cell infiltration. The underlying mechanisms are not still poorly understood. Here, we demonstrate that O-linked N-acetylglucosamine (O-GlcNAcylation), a prevalent form of protein glycosylation, contributes to establishing the immunosuppressive niche through regulating the metabolic and non-metabolic functions of uridine diphosphate glucose dehydrogenase (UGDH). Tumor cells carrying O-GlcNAcylation-deficient UGDH showed reduced xenograft tumor growth and improved survival in mice. Cytometry by time-of-flight (CyTOF) analysis suggests UGDH O-GlcNAcylation negatively correlates with cytotoxic CD8+ T cell infiltration. O-GlcNAcylation on serine 350 of UGDH is located within the UDP-binding domain, and the subsequent extensive all-atom molecular dynamics simulations reveal that O-GlcNAcylation reinforces hydrogen-bonding interaction and enzymatic activity of UGDH, leading to enhanced hyaluronic acid (HA) synthesis in the extracellular matrix. Moreover, O-GlcNAcylation of UGDH reduces CD8+ T cell infiltration by decreasing the chemokine CXCL10 expression. Specifically, O-GlcNAcylation enhances UGDH interaction with KPNA2 to compete with STAT1, and suppresses translocation of STAT1 into the nucleus, thereby transcriptionally downregulating CXCL10 expression. Thus, our study identifies UGDH O-GlcNAcylation as a key regulator of tumor immunity and further suggests a potential strategy for enhancing immunotherapy.

Figures